Claudin-6 was notably upregulated in 20 different cancers; however, its expression was significantly reduced in GBM tissues, chromophobe renal cell carcinoma (KICH), acute myeloid leukemia (LAML), clear cell renal cell carcinoma (KIRC and LGG) (49). Here, CLDN6 is linked to cancer.